Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Heart selenoproteins status of metabolic syndrome-exposed pups: A potential target for attenuating cardiac damage.

Serrano A, Nogales F, Sobrino P, Murillo ML, Carreras O, Ojeda ML.

Mol Nutr Food Res. 2016 Dec;60(12):2633-2641. doi: 10.1002/mnfr.201600511. Epub 2016 Oct 10.

PMID:
27520709
2.

Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy.

Estrada V, Monge S, Gómez-Garre MD, Sobrino P, Masiá M, Berenguer J, Portilla J, Viladés C, Martínez E, Blanco JR; CoRIS and the HIV Biobank integrated in the Spanish AIDS Research Network..

HIV Med. 2016 Oct;17(9):653-61. doi: 10.1111/hiv.12368. Epub 2016 Mar 3.

PMID:
26935006
3.

Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013.

Sobrino-Vegas P, Moreno S, Rubio R, Viciana P, Bernardino JI, Blanco JR, Bernal E, Asensi V, Pulido F, del Amo J, Hernando V; Cohorte de la Red de Investigación en Sida, Spain..

J Infect. 2016 May;72(5):587-96. doi: 10.1016/j.jinf.2016.01.017. Epub 2016 Feb 24.

4.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration..

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

5.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration., Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

6.

Overall and cause-specific mortality in HIV-positive subjects compared to the general population.

Alejos B, Hernando V, López-Aldeguer J, Segura F, Oteo JA, Rubio R, Sanvisens A, Sobrino P, Del Amo J, Coris C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19711. doi: 10.7448/IAS.17.4.19711. eCollection 2014.

7.

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy.

Estrada V, Monge S, Gómez-Garre D, Sobrino P, Berenguer J, Bernardino JI, Santos J, Zamora AM, Martínez E, Blanco JR.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19544. doi: 10.7448/IAS.17.4.19544. eCollection 2014.

8.

Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes.

Monge S, Diez M, Pulido F, Iribarren JA, Campins AA, Arazo P, Montero M, Miro JM, Moreno S, Del Amo J; Spanish AIDS Research Network Cohort (CoRIS)..

Int J Tuberc Lung Dis. 2014 Jun;18(6):700-8. doi: 10.5588/ijtld.13.0778.

PMID:
24903942
9.

Anal human papillomavirus genotype distribution in HIV-infected men who have sex with men by geographical origin, age, and cytological status in a Spanish cohort.

Torres M, González C, del Romero J, Viciana P, Ocampo A, Rodríguez-Fortúnez P, Masiá M, Blanco JR, Portilla J, Rodríguez C, Hernández-Novoa B, del Amo J, Ortiz M; CoRIS-HPV Study Group..

J Clin Microbiol. 2013 Nov;51(11):3512-20. doi: 10.1128/JCM.01405-13. Epub 2013 Aug 21.

10.

Inequalities in HIV disease management and progression in migrants from Latin America and sub-Saharan Africa living in Spain.

Monge S, Alejos B, Dronda F, Del Romero J, Iribarren JA, Pulido F, Rubio R, Miró JM, Gutierrez F, Del Amo J; CoRIS..

HIV Med. 2013 May;14(5):273-83. doi: 10.1111/hiv.12001. Epub 2012 Nov 21. Erratum in: HIV Med. 2014 Jan;15(1):64.

11.

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.

May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC)..

Int J Epidemiol. 2012 Dec;41(6):1807-20. doi: 10.1093/ije/dys164. Epub 2012 Nov 12.

12.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration..

AIDS. 2012 Aug 24;26(13):1691-705.

13.

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.

Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord., Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G.

Int J Epidemiol. 2012 Apr;41(2):433-45. doi: 10.1093/ije/dyr164. Epub 2011 Nov 28.

PMID:
22493325
14.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration..

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28.

15.

HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain.

Tuma P, Pineda JA, Labarga P, Vidal F, Rodriguez C, Poveda E, Santos J, Gonzalez-García J, Sobrino P, Tural C, Soriano V; CoRIS Study Group..

Antivir Ther. 2011;16(4):585-9. doi: 10.3851/IMP1778.

PMID:
21685546
16.

Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections.

Dronda F, Sobrino P, Hernández-Novoa B, Caro-Murillo AM, Montero M, Iribarren JA, Sanz J, Del Mar Alonso M, Labarga P, Bernal E, Moreno S; CoRIS..

Curr HIV Res. 2011 Jun;9(4):229-36. doi: 10.2174/157016211796320324.

PMID:
21631429
17.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration., Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

18.

Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.

Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients., Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange S, Riera M, Mussini C, Gutiérrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN.

Lancet. 2010 Jul 31;376(9738):340-5. doi: 10.1016/S0140-6736(10)60932-4. Epub 2010 Jul 15.

19.

Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.

Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group., Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Chene G, Egger M.

Antivir Ther. 2009;14(8):1065-74. doi: 10.3851/IMP1462.

20.

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

HIV-CAUSAL Collaboration., Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA.

AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283.

Supplemental Content

Loading ...
Support Center